Avinger, Inc. (AVGR)
NASDAQ: AVGR · Real-Time Price · USD
0.797
-0.035 (-4.25%)
Dec 3, 2024, 11:45 AM EST - Market open
Avinger Revenue
Avinger had revenue of $1.65M in the quarter ending September 30, 2024, a decrease of -9.19%. This brings the company's revenue in the last twelve months to $7.26M, down -6.26% year-over-year. In the year 2023, Avinger had annual revenue of $7.65M, down -7.51%.
Revenue (ttm)
$7.26M
Revenue Growth
-6.26%
P/S Ratio
0.32
Revenue / Employee
$100,861
Employees
72
Market Cap
2.55M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.65M | -621.00K | -7.51% |
Dec 31, 2022 | 8.27M | -1.86M | -18.33% |
Dec 31, 2021 | 10.13M | 1.37M | 15.63% |
Dec 31, 2020 | 8.76M | -370.00K | -4.05% |
Dec 31, 2019 | 9.13M | 1.22M | 15.36% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Xylo Technologies | 57.64M |
Scorpius Holdings | 10.04M |
Petros Pharmaceuticals | 4.02M |
NanoVibronix | 3.29M |
Akanda | 2.51M |
Cyclacel Pharmaceuticals | 74.00K |
HeartSciences | 18.60K |
AVGR News
- 25 days ago - Avinger, Inc. (AVGR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Avinger Reports Third Quarter 2024 Results - Accesswire
- 5 weeks ago - Avinger to Announce Third Quarter 2024 Results on November 7, 2024 - Accesswire
- 5 weeks ago - Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention - Accesswire
- 2 months ago - Avinger Announces Issuance of New U.S. Patent and Receives Notices of Allowance for Five Additional U.S. Patents - Accesswire
- 3 months ago - Avinger Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device - Accesswire
- 4 months ago - Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Avinger Reports Second Quarter 2024 Results - Accesswire